Obstructive Lung Diseases |

Efficacy of Olodaterol Once Daily (QD) via Respimat in GOLD 2/3 COPD Patients Not Receiving Background Therapy: Pooled Data From 48-Week Studies FREE TO VIEW

Gary Ferguson, MD; Paul Sachs, MD; Alan Hamilton, PhD; Kay Tetzlaff, MD; Lawrence Korducki, MA; Andrea Koch, MD
Author and Funding Information

Pulmonary Research Institute of Southeast Michigan, Livonia, MI

Chest. 2013;144(4_MeetingAbstracts):727A. doi:10.1378/chest.1702133
Text Size: A A A
Published online


SESSION TITLE: COPD Treatment Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: The efficacy of olodaterol 5 µg QD versus placebo has been demonstrated in a broad COPD population with moderate to very severe disease receiving background of usual-care COPD therapies. A post hoc pooled analysis was conducted to evaluate the efficacy of olodaterol in a subgroup of patients with moderate to severe disease (GOLD 2-3) who were not receiving background maintenance bronchodilator therapies (trial conditions more closely corresponding to traditional COPD bronchodilator studies).

METHODS: Four randomized, double-blind, placebo-controlled, parallel-group studies (NCT00782210; NCT00782509; NCT00793624; NCT00796653) investigated olodaterol 5 or 10 µg QD via Respimat® versus placebo for 48 weeks, with patients allowed to continue their usual COPD care during the trial, including SAMA, LAMA, ICS, and xanthines. Data from a subgroup of GOLD 2 or 3 patients not receiving SAMA, LAMA, xanthines, or beta-blockers as maintenance therapy during the study was pooled for analysis.

RESULTS: Of the 3104 patients from the total pooled study populations, 1127 were included in the subgroup. A higher treatment response to olodaterol 5 µg versus placebo over 48 weeks was observed in the subgroup compared to the full analysis set (FAS). Mean difference from placebo for FEV1 AUC0-3 response was 0.186 L in the subgroup compared to 0.161 L in the FAS. Mean trough FEV1 response (versus placebo) was 0.101 L in the subgroup compared to 0.071 L in the FAS. Within the subgroup, both FEV1 AUC0-3 and trough FEV1 responses were higher in GOLD 2 (0.197 and 0.121 L, respectively) compared to GOLD 3 patients (0.161 and 0.064 L, respectively).

CONCLUSIONS: The magnitude of bronchodilator response to olodaterol is influenced by baseline disease severity and background concomitant therapies.

CLINICAL IMPLICATIONS: Careful attention to the severity of disease and permitted background therapies is required when interpreting results from bronchodilator studies in COPD. Funding: Boehringer Ingelheim. Editorial assistance: Complete HealthVizion.

DISCLOSURE: Gary Ferguson: Grant monies (from industry related sources): Institution received grant rom Clinical trial centre for PRISM, Other: Institution received fees in return for Gary Ferguson's work as co-ordinating investigator , Other: Writing assistance received on manuscripts by sponsor of study to which manuscript relates Paul Sachs: Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim Alan Hamilton: Employee: Boehringer Ingelheim Kay Tetzlaff: Employee: Boehringer Ingelheim Lawrence Korducki: Employee: Boehringer Ingelheim Andrea Koch: Fiduciary position (of any organization, association, society, etc, other than ACCP: Member of the board for German Atemwegsliga, German Society of Pneumology (DGP), Other: Received fees for expert testimony from Boehringer Ingelheim, Germany, Berlin-Chemie, GlaxoSmithKline,, Grant monies (from industry related sources): MSD, Boehringer Ingelheim, Actelion, Bayer, Other: Travel and accommodation expenses received for activities carried out on behalf of Boehringer Ingelheim Germany,

Submitted to regulatory authority for marketing approval




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543